BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New Cooperation On Identification Of Multiple Sclerosis Pathogens Established Between GANYMED Pharmaceuticals AG And The University Of Rotterdam


10/19/2005 5:10:28 PM

Within the scope of GANYMED's MicroGATETM project GANYMED Pharmaceuticals AG and the Medical Center of Erasmus University Rotterdam established a cooperation for the purpose of identifying new pathogens. The neurological branch of the University Hospital of Rotterdam (Director: Prof. Dr. P.A.E. Sillevis Smitt) is very active as reference hospital and has great expertise in Multiple Sclerosis (MS). The University of Rotterdam is supporting GANYMED in the field of identification of MS pathogens. "The identification of new MS pathogens will open up new possibilities for therapy and diagnostics of MS patients", PD Dr. Özlem Türeci, CSO of GANYMED, underlined the importance of the cooperation. "We are looking forward to this cooperation and are enthusiastic to have a share in improving diagnosis and therapy of multiple sclerosis", emphasizes Dr. R. Q. Hintzen, project leader of the MS program at the Medical Center of the University of Rotterdam, the interest of his research group.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES